Fennec Pharmaceuticals Reports Strong Q1 2025 Growth

Fennec Pharmaceuticals ( (FENC) ) has released its Q1 earnings. Here is a breakdown of the information Fennec Pharmaceuticals presented to its investors.

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK, a therapy aimed at reducing the risk of ototoxicity in pediatric cancer patients undergoing cisplatin treatment. The company operates primarily within the pharmaceutical sector, with a unique focus on addressing hearing loss in children affected by cancer treatments.

In its first quarter of 2025, Fennec Pharmaceuticals reported total net revenues of $8.8 million, marking an 18% increase compared to the same period last year. This growth is attributed to the company’s refined sales strategy and enhanced patient support services, as well as the commercial availability of PEDMARQSI in Germany and the United Kingdom.

Key financial highlights include a notable increase in net product sales driven by new accounts in the adolescent and young adult cancer patient population. The company also reported a decrease in selling and marketing expenses, primarily due to the elimination of pre-commercialization expenses in Europe. However, general and administrative expenses saw an increase due to non-cash stock-based compensation.

Looking ahead, Fennec Pharmaceuticals remains optimistic about its growth trajectory, focusing on deepening relationships with key accounts and expanding its customer base. The company is committed to maintaining its momentum and delivering value to patients, providers, and shareholders.